Article | September 20, 2022

Why "Off-The-Shelf" Devices Do Not Circumvent Design Controls

Source: Kymanox Corporation

By Jason Miller, Head of Engineering, Kymanox Corporation, Morrisville, North Carolina


Utilizing Off-The-Shelf (OTS) devices for drug delivery can offer significant advantages to development programs in timeline and risk mitigation (1). The performance of OTS devices is generally well understood from previous applications. In addition, the manufacturing processes are established, and the device constituent has completed documentation in place to support a sponsor’s combination product application.

Considering these advantages, it can be easy to fall into the trap of assuming that the OTS suppliers will take care of all design control requirements and that those requirements will carry over to the sponsor’s combination product. Unfortunately, that is not the case, and the responsibility for meeting the necessary design control requirements rests on the combination product sponsor, rather than the manufacturer of the OTS device.

Prior works have discussed some of the intricacies in choosing between an OTS and a novel device for a drug delivery system (1), and this article focuses on the design control responsibilities of a sponsor when using OTS devices for drug delivery.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader